ResMed Stock Hits 52-Week Low on Mixed Q3 Earnings and $340M Acquisition

Amid shifting dynamics in the healthcare sector and heightened investor scrutiny, ResMed shares faced significant selling pressure that drove the stock to a new 52-week low. According to reports, the stock touched $198.60, marking a total decline of 18.79% over the past year. This price action followed the release of mixed Q3 2026 financial results, where earnings per share managed to beat analyst forecasts, but total revenue fell short of estimates. Additionally, the company announced a definitive agreement to acquire Noctrix Health for $340 million.

The decline occurs as investors weigh the long-term impact of GLP-1 weight-loss drugs on the demand for sleep apnea devices, ResMed's core business. In comparison to peers, market data shows that Philips (PHG) has seen some stabilization following major legal settlements, while ResMed continues to struggle with revenue growth concerns. Per market data, the divergence between strong earnings and missing revenue targets suggests underlying challenges in sales volume or market penetration that the Noctrix acquisition aims to address.

Technically, RMD stock remains under pressure as of the close on May 29, 2026, with the $198.60 level serving as a critical support zone. Traders should watch for upcoming catalysts in the economic calendar, specifically the US CB Consumer Confidence data, which may provide insight into discretionary healthcare spending. Furthermore, the market will look for integration details regarding the Noctrix Health deal to determine its impact on the company's debt profile and future cash flows.